Liquid Biopsy Market Prospects with Study of Key Players & Revenue to Healthy Growth Forecast To 2028
The global liquid biopsy market revenue is expected to expand at a lucrative CAGR over the forecast period. Technological advancements in liquid biopsy and enhanced view of tumor offered liquid biopsy technology are the major factors expected to drive growth of the target market over the forecast period.
The global liquid biopsy market report has been segmented on the basis of application, type, biomarker, technology, and region.
On the basis of type, the target market is segmented into blood sample-based, urine sample-based, and other bio fluids (tissue fluids and saliva) based. The blood sample-based type segment is expected to register significant growth in terms of revenue over the forecast period, owing to availability of preexisting applications and purification methods.
On the basis of biomarker, the target market is segmented into circulating tumor cells (CTC), circulating tumor DNA (ctDNA), and exosomes. On the basis of technology, the target market is segmented into multi-gene-parallel analysis (NGS) and single gene analysis (PCR Microarrays). On the basis of application, the target market is segmented into therapy selection for metastatic breast cancer (MBS), therapy selection for other metastatic cancer, and molecular health monitoring. The therapy selection for other metastatic cancer application segment is expected to register significant growth over the forecast period, owing to increasing incidence of metastatic cancer across the globe.
To Get Sample Copy of Report visit @ https://marketresearch.biz/report/liquid-biopsy-market/request-sample/
Based on the region the liquid biopsy market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America is estimated to be highest share in terms of revenue over the forecast period, owing to technological development, rising awareness of cancer, and government initiatives in medical industry in various countries in the region. The market in Asia Pacific is expected to register significant share in terms of revenue over the forecast period.
Key players operating in the global liquid biopsy market include Guardant Health Inc., Personal Genome Diagnostics, Inc., Biocept, Inc., Adaptive Biotechnologies Corporation, Cynvenio Biosystems, Inc., NeoGenomics Laboratories, Inc., QIAGEN, Inc., TrovaGene, Inc., RainDance Technologies, Inc., and Exact Sciences Corporation.